Kidswell Bio Corporation · TSE:4584
Kidswell Bio — Q1 FY2025 Earnings Presentation
16 slides from Kidswell Bio's earnings presentation, Aug 14, 2024
Slide 1: Financial Results for the First Quarter of Fiscal Year Ending March 31, 2025
Biotech Striving for Value Creation - For a Comprehensive Healthcare System for Children, Families, and Society - Security Code: 4584 Financial Results for the First Quarter of Fiscal Year Ending March 31, 2025 August 14, 2024 Kidswell Bio Corporation © 2024 Kidswell Bio Corporation. 1
Slide 2: Agenda
◆ Financial Highlights Agenda ◆ Initiatives in Maximizing Corporate Value © 2024 Kidswell Bio Corporation. 2
Slide 3: Financial Highlights
Financial Highlights © 2024 Kidswell Bio Corporation. 3
Slide 4: Income Statement
Income Statement (Unit: thousand yen) FY2023 FY2024 Subject 1Q Results 1Q Results 1Q Results Year-on- KWB Non-consolidated (non-consolidated) (consolidated) year ratio (non-consolidated) Gross sales 45,979 482,957 -- 482,066 Cost of goods sold 853 259,332 -- 259,332 Gross profit 45,126 223,625 -- 22
Slide 5: Balance Sheet
Balance Sheet (Unit: thousand yen) Subject 4Q FY2024 (non-consolidated) 1Q FY2025 (consolidated) Current assets 4,924,221 4,448,427 (Cash and cash equivalents) 2,231,411 1,166,900 (Accounts receivable) 881,407 598,493 (Products) -- -- (In-process inventory) 875,654 1,280,344 (Advance payments) 739,5
Slide 6: Outlook for the current fiscal year (ending March 31, 2025)
Outlook for the current fiscal year (ending March 31, 2025) • Due to the difficulty in generating reliable earnings forecast figures for the current fiscal year (ending March 31, 2025) at this time, only sales forecast is provided as a range. • The forecast of operating income, ordinary income and n
Slide 7: Biosimilar Business Growth and Future Earnings Outlook
Biosimilar Business Growth and Future Earnings Outlook • With the approval of GBS-010 and the additional indications of GBS-007 indications in the last fiscal year, further earnings growth is expected in this fiscal year and beyond. • While there are concerns about the impact of the recent sharp app
Slide 8: Impact of Foreign Exchange Fluctuations on Business Performance (Profit)
Impact of Foreign Exchange Fluctuations on Business Performance (Profit) • Gross profit margin: All biosimilar APIs are manufactured overseas, so exchange rate fluctuations have a direct impact. ➢ The sharp depreciation of the yen since 2022 has led to an increase in yen-denominated cost of sales an
Slide 9: Initiatives in Maximizing Corporate Value
Initiatives in Maximizing Corporate Value © 2024 Kidswell Bio Corporation. 9
Slide 10: Plans for Major Initiatives: Biosimilar Business (Kidswell Bio)
Plans for Major Initiatives: Biosimilar Business (Kidswell Bio) FY2024 (current fiscal year) FY2025 (next fiscal year) Maintenance of stable supply by adjusting manufacturing schedules and responding to deviations Launched Promote measures to reduce manufacturing costs, etc. to improve profitability
Slide 11: Plans for Major Initiatives: Cell Therapy Business (S-Quatre)
Plans for Major Initiatives: Cell Therapy Business (S-Quatre) FY2024 (current fiscal year) FY2025 (next fiscal year) SHED administration and Support for promotion of clinical research on cerebral palsy at Nagoya University observation in progress. First generation Contract signing is Discussions wit
Slide 12: Plans for Major Initiatives: Management Strategy (whole group)
Plans for Major Initiatives: Management Strategy (whole group) Maximize corporate value, drive stock price recovery and business growth FY2024 (current fiscal year) FY2025 (next fiscal year) (1) Efficient use of management resources Restructuring of corporate culture and systems Maximize utilization
Slide 13: Tentative IR Schedule for FY2024
Tentative IR Schedule for FY2024 IR Basic Policy • Improve communication with shareholders and investors to enhance their understanding of KWB and enable them to evaluate KWB appropriately • Improve the quality of the information provided instead of simply providing frequent briefings Tentative Annu
Slide 14: Maximizing the corporate value of KWB
Maximizing the corporate value of KWB As a biosimilar development partner backed by an overwhelming track record, and as a global top runner in SHED drug discovery, work together with partner companies to improve corporate value. Biosimilar Business Cell Therapy Business • Maximize revenues from the
Slide 15: KIDS WELL, ALL WELL
KIDS WELL, ALL WELL All for Kids, Kids for All © 2024 Kidswell Bio Corporation. 15
Slide 16: Cautionary Statement
Cautionary Statement This information material is provided for understanding Kidswell Bio Corporation (“KWB”), not for soliciting investment in KWB shares. Information provided in this material may contain so-called “forward-looking statements.” These statements are based on current expectations, fo